• Home
  | 
• Full Prescribing Information
  | 
• About CRESTOR
  | 
• Clinical Experience
  | 
• Resources
  | 
• Patient Support
  | 
• References

Use in Patients With Diabetes

In this section you can review results from clinical trials in which CRESTOR^® (rosuvastatin calcium) was used as an adjunct to diet in patients with type 2 diabetes and dyslipidemia.

TRIALS: ANDROMEDA, CORALL, and URANUS

Back to top

LDL-C goal attainment (<100 mg/dL) in patients with type 2 diabetes and dyslipidemia^1,2,3

*In 3 titration trials of patients with type 2 diabetes and dyslipidemia treated with a starting dose of CRESTOR 10 mg.

In the ANDROMEDA trial (n=240), 94% reached LDL-C goal of <96.5 mg/dL at 8 weeks. There was a mean LDL-C reduction of 51% from baseline of 131 mg/dL. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.¹

In the CORALL trial (n=130), 82% reached LDL-C goal of <100 mg/dL at 6 weeks. There was a mean LDL-C reduction of 46% from baseline of 164 mg/dL. The primary end point, the percentage change from baseline in ApoB/ApoA 1 ratio after 6 weeks, was not significantly different between CRESTOR and atorvastatin. LDL-C goal achievement was another end point.²

In the URANUS trial (n=232), 65% reached LDL-C goal of <100 mg/dL at 4 weeks. There was a mean LDL-C reduction of 48% from baseline of 178 mg/dL. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.³

1 2 3

Adapted from the ANDROMEDA trial.¹ ANDROMEDA was a randomized, double-blind, multicenter, parallel-group, forced-titration trial comparing the efficacy and safety of CRESTOR (10 mg and 20 mg) and atorvastatin (10 mg and 20 mg) in patients with type 2 diabetes mellitus and dyslipidemia. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.

Adapted from the CORALL trial.² CORALL was an 18-week, randomized, multicenter, open-label, parallel-group, forced-titration trial comparing the efficacy and safety of CRESTOR with atorvastatin in 263 patients with type 2 diabetes mellitus and dyslipidemia. In this trial, patients were randomized to receive CRESTOR 10 mg or atorvastatin 20 mg for 6 weeks. At week 6, doses were increased to CRESTOR 20 mg or atorvastatin 40 mg, and at week 12, doses were increased to CRESTOR 40 mg or atorvastatin 80 mg for a further 6 weeks. Statistical comparisons were not made across the dose range, only across the same time period (6 weeks vs 6 weeks, 12 weeks vs 12 weeks, 18 weeks vs 18 weeks). The primary end point of CORALL, the percentage change from baseline in ApoB/ApoA-1 ratio at 6 weeks, was not significantly different between CRESTOR and atorvastatin.

Adapted from the URANUS trial.³ URANUS was a 16-week, randomized, double-blind, forced-titration trial comparing CRESTOR and atorvastatin in 465 type 2 diabetics with dyslipidemia. Patients were randomized to CRESTOR 10 mg or atorvastatin 10 mg for 4 weeks and then titrated up if goal was not met. The primary end point, percentage change from baseline in LDL-C at 16 weeks, was significantly better in the rosuvastatin group (10 to 40 mg) when compared with the atorvastatin group (10 to 80 mg).

TRIAL: CORALL

Back to top

LDL-C reductions vs atorvastatin in patients with type 2 diabetes and dyslipidemia²

*P<.05 vs atorvastatin 20 mg
^†P<.05 vs atorvastatin 40 mg.
^‡P<.01 vs atorvastatin 80 mg.

CRESTOR n=130
atorvastatin n=132

Mean baseline LDL-C: 163 mg/dL to 171 mg/dL.

Adapted from the CORALL trial.² CORALL was an 18-week, randomized, multicenter, open-label, parallel-group, forced-titration trial comparing the efficacy and safety of CRESTOR with atorvastatin in 263 patients with type 2 diabetes mellitus and dyslipidemia. In this trial, patients were randomized to receive CRESTOR 10 mg or atorvastatin 20 mg for 6 weeks. At week 6, doses were increased to CRESTOR 20 mg or atorvastatin 40 mg, and at week 12, doses were increased to CRESTOR 40 mg or atorvastatin 80 mg for a further 6 weeks. Statistical comparisons were not made across the dose range, only across the same time period (6 weeks vs 6 weeks, 12 weeks vs 12 weeks, 18 weeks vs 18 weeks). The primary end point of CORALL, the percentage change from baseline in ApoB/ApoA-1 ratio at 6 weeks, was not significantly different between CRESTOR and atorvastatin.

TRIAL: ANDROMEDA

Back to top

LDL-C reductions vs atorvastatin in patients with type 2 diabetes and dyslipidemia¹

P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs
atorvastatin 20 mg.

Mean baseline LDL-C: 131 mg/dL

Week 8:
CRESTOR 10 mg n=240
atorvastatin 10 mg n=240

Week 16:
CRESTOR 20 mg n=227
atorvastatin 20 mg n=229

Adapted from the ANDROMEDA trial.¹ ANDROMEDA was a randomized, double-blind, multicenter, parallel-group, forced-titration trial comparing the efficacy and safety of CRESTOR (10 mg and 20 mg) and atorvastatin (10 mg and 20 mg) in patients with type 2 diabetes mellitus and dyslipidemia. The primary end point was the percentage change from baseline in LDL-C after 16 weeks.

Important Safety Information for CRESTOR Tablets

• CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with statins, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, lopinavir/ritonavir, or atazanavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• It is recommended that liver enzyme tests be performed before the initiation of CRESTOR and if signs or symptoms of liver injury occur. All patients treated with CRESTOR should be advised to promptly report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including CRESTOR. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with CRESTOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart CRESTOR
• CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease
• CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs
• Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with CRESTOR. These findings were more frequent in patients taking CRESTOR 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
• Increases in HbA1c and fasting serum glucose levels have been reported with statins, including CRESTOR
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^#‡‡
• Rare postmarketing reports of cognitive impairment (eg, memory loss, forgetfulness, amnesia, memory impairment, confusion) have been associated with statin use, including CRESTOR. These reports are generally nonserious and reversible upon statin discontinuation
• The dose range for CRESTOR is 5 mg to 40 mg orally once daily. The usual starting dose is 10 mg to 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose. After initiation or upon titration of CRESTOR, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg

Indications

• CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
• CRESTOR is indicated to reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease

Read full Prescribing Information (PDF - 152k)

Please see the full Prescribing Information available at CrestorTouchPoints.com
CRESTOR is licensed from SHIONOGI & CO, LTD, Osaka, Japan.

CRESTOR is a registered trademark of the AstraZeneca group of companies.

©2012 AstraZeneca. All rights reserved. 1569505 3/12

• Privacy Statement | 
• Legal Information | 
• Contact Us | 
• Site Map

  This product information is intended for US health care professionals only.